No FDA advisory-committee or Type B meeting is publicly scheduled for TRP-8803 within 12 weeks; the '72-patient commercialisation' claim gets corrected to a designation.

A company called Terran Biosciences has a drug program called TRP-8803, and someone described it as being on a path to commercialization after testing in 72 patients. But the FDA (the US drug regulator) requires far more evidence — typically hundreds or thousands of patients across multiple studies — before any drug can be sold. What the company likely received is a special designation (a kind of official encouragement), not a green light to sell anything.

A 72-patient multi-indication basket is early; 'commercialisation' is marketing language. FDA process requires far more before any commercial pathway is real.